secwatch.observer — SEC 8-K summary
======================================

Issuer:     TENAX THERAPEUTICS, INC. (TENX)
CIK:        0000034956
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001654954-23-014103
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA clears IND for Tenax's TNX-103 (oral levosimendan) for PH-HFpEF; Phase 3 LEVEL study to start Q4 2023
--------------------------------------------------------------------------------

- FDA cleared IND for TNX-103 (oral levosimendan) to treat PH-HFpEF, enabling Phase 3 LEVEL study in Q4 2023.
- FDA agreed to 6-minute walk distance as primary endpoint; no requirement for cardiovascular outcomes trial.
- Patent protection for oral levosimendan in PH-HFpEF until end of 2040; no FDA-approved treatments exist.
- More than 2/3 of research sites selected; 90% of prior HELP study sites agreed to participate.
- Estimated North American patient population >2 million by 2030; high unmet medical need.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/34956/000165495423014103/0001654954-23-014103-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/34956/000165495423014103/tenx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-23-014103

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer